← Human Trials & Peer-Reviewed Studies

The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study

Plain-language guide to PMID 18251131 (2007): randomized controlled trial study of Terlipressin.

Key Facts

PMID
18251131
Journal
Hepato-gastroenterology
Year
2007
Study type
Randomized Controlled Trial
Authors
Lata J et al. (11 authors)
Registered trial
NCT00108355

What This Study Did, in Plain Language

What Was Tested

Researchers studied Terlipressin in this randomized controlled trial publication.

Postparacentesis circulatory dysfunction is the most severe complication of ascites paracentesis.

The aim of their study was to compare the standard treatment with the administration of a vasoconstrictor terlipressin.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Terlipressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The blood pressure, heart rate, diuresis, electrocardiograph, standard biochemical and hematological parameters, sodium, potassium and nitrogen urinary excretion, aldosterone and renin activity in the blood plasma were monitored for a period of 72 hours.

What Was Measured

The subject headings attached to it are Albumins, Aldosterone, Ascites, Blood Pressure, Heart Rate, Hemodynamics and Lypressin.

What This Means in Plain Language

The paper is a randomized study of Terlipressin.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Hepato-gastroenterology), a journal based in Greece.

More context: the Terlipressin compound page, all human trials.

Our Notes on the Compound

Terlipressin: A synthetic vasopressin analog (Terlivaz) used for kidney failure in advanced liver disease and for variceal bleeding.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.